Abstract
Background. Voriconazole treatment increases early survival of allogeneic hematopoietic stem cell transplant recipients with invasive aspergillosis. We investigated whether this survival advantage translates into an increased long-term survival.
Design and Methods. This retrospective study involved all patients with an invasive aspergillosis diagnosis transplanted between September 1997 and December 2008, at SaintLouis Hospital, Paris. The primary endpoint was survival up to 36 months. Survival analysis before and after 12 weeks, as well as cumulative incidence analysis in a competing risks framework, were used to assess the effect of voriconazole treatment and other factors on mortality.
Results. Among 87 patients, 42 received first-line voriconazole and 45 received another antifungal agent. The median survival time was 2.6 months, and the survival rate at 36 months was 18%. Overall, the survival rates of the two groups were significantly different.
Specifically, there was a dramatic difference in survival rates up to 10 months postaspergillosis diagnosis, but no significant difference after this time. Over the first 36 months as a whole, no significant difference in survival rate was observed between the two groups.
First-line voriconazole significantly decreased aspergillosis-attributable mortality. However, first-line voriconazole patients experienced a significantly higher probability of death from a non-aspergillosis-attributable cause.
Conclusions.
Although the prognosis for invasive aspergillosis after stem cell transplantation has dramatically improved with the use of voriconazole, this major advance in care does not translate into an increased long-term survival for these severely immunocompromised patients.
INTRODUCTION
Invasive aspergillosis (IA) is a common cause of infection-related mortality in hematopoietic stem cell transplant (HSCT) recipients, although several large studies have demonstrated that post-transplant IA outcomes in HSCT patients have significantly improved over the last decade. This improvement in response rate and survival is attributed to the availability of better antifungal agents (i.e., agents that are more effective and better tolerated). In addition,
although it is more difficult to demonstrate, the improvement is also attributed to earlier infection diagnoses due to better physician awareness and the availability of effective diagnostic tools, such as galactomannan (GM) testing and CT scanning (1) (2) (3) (4) (5) . Voriconazole treatment appears to be independently associated with improved survival through a decrease in IA-attributable mortality (1, 2, 4, 6, 7). These findings, and others, legitimize the universal recommendation of voriconazole as a first-line IA treatment in haematological as well as other immunocompromised patients (8) (9) (10) (11) .
Most studies have examined 3-, 4-or 6-month survival rates of HSCT recipients with IA, but immunosuppression is a persistent difficulty in this patient population. As such, we examined whether the early survival advantage could translate into an increase in long-term overall survival in our series of HSCT recipients with IA.
DESIGN and METHODS
We retrospectively studied all consecutive patients receiving an allogeneic HSCT between and patients with non-malignant diseases were considered to be standard-risk patients, as opposed to poor-risk patients. Causes of death were defined as follows. For death without aspergillosis, the death had to be clearly attributed to a cause other than IA. The subject had to have no evidence of IA upon autopsy (when available) or had to have a complete IA response (CR) at the last assessment prior to death. For death with aspergillosis, the death had to be clearly attributed to a cause other than IA, even though at the time of death or last assessment there was evidence of IA. Any death occurring in case of stable/progression of aspergillosis was assessed as from aspergillosis. The GM antigen was detected in the serum using a antifungal treatment were assessed as recently recommended (13) , and a data review committee assessed the responses in each case (GS1, PR and AB).
Statistical considerations
All data are reported as count (percent), median (range). The date of IA diagnosis was considered to be the start of the study for each subject. The overall survival curves were estimated using a Kaplan-Meier product-limit estimator and compared using logrank or Gehan-Wilcoxon tests, according to whether the proportional hazards could be assumed or not. The factors associated with survival were analysed using Cox proportional hazards models. Separate models were estimated for survival up to 12 weeks and for survival between 12 weeks and 36 months in patients surviving at least 12 weeks. The proportional hazards assumption was checked by examination of the Schoenfeld residuals and a Grambsch and Therneau's lack-of-fit test (14) . The factors analysed were first-line voriconazole receipt, age, disease risk, donor type, stem cell source, myeloablative versus reduced intensity conditioning, patient CMV status, active graft-versus-host-disease (GVHD) at IA diagnosis, neutrophil count and cumulated dose of steroids in the week preceding the IA diagnosis, and sites of pulmonary infection (unilateral versus bilateral). For survival after 12 weeks, CR prior to 12 weeks was also considered. All deaths from IA, with IA or without IA were analysed in a competing risk framework. Cumulative incidence curves were estimated using a standard methodology (15) . The cumulative incidence curves were compared using Gray's tests (16) .
The cumulative incidence of partial responses (PR) and CR was also estimated in a competing risks framework, with death being the competing event. To further analyse the relationship between CR and survival, multistate models were used, and CR was also considered as a time-dependent variable in the proportional hazards models. All tests were two-tailed and Pvalues <0.05 were considered significant. All analyses were performed using the statistical software R version 2.10.1 (R Development Core Team. Vienna, 2009). The multistate models were fitted using the mstate package (17) . patients in the voriconazole group received another antifungal as a second-line treatment, initiated after a median time of 28 days (9 to 400 days). Voriconazole was stopped because of intolerance (n=10), insufficient efficacy (n=5), concomitant mucormycosis diagnosis (n=2).
RESULTS

During the period between
The reason was not specified in one case. Second line antifungals were caspofungin (n=6), posaconazole (n=6), liposomal amphotericin B (n=5), and itraconazole in one case.
Voricoconazole was later resumed in ten patients.
The characteristics of the patients with IA and their causes of death, separated by voriconazole as a first-line treatment, are shown in Table 1 .
Survival
The median follow-up duration was 70 months overall (range: 11 to 130 months), 44 months in the voriconazole group and 88 months in the other group. Median survival was 2.6 months, and the overall survival rate at 36 months was 18% (95% CI: 11-28%) ( Figure 1A) . Overall, the survival rates of the two groups were significantly different (p=.020), with a median survival time of 3.3 months in the voriconazole group and 1.5 months in the non-voriconazole group. However, while the differences in survival were quite dramatic prior to 10 months, the two survival curves became very closely aligned after one year. At 12 months, the survival rate was 26% (95% CI: 15-43%) in the voriconazole group and 20% (95% CI: 11-36%) in the non-voriconazole group. At 18 months, the percentages of surviving patients were identical in both groups: 20% (95% CI: 11-36%) in patients who did not receive voriconazole as first-line treatment and 21% (95% CI: 11-38%) in patients who did receive voriconazole ( Figure 1B ).
The effect of voriconazole as a first-line treatment on mortality was not constant over time p=.0005) ( Table 2 ). An analysis of long-term mortality risk factors (up to 36 months) for survivors at 12 weeks failed to identify any significant predictor of mortality (Table 3) . Over the first 36 months, no significant gain in survival was observed in the voriconazole group as compared with the non-voriconazole group (mean difference 1.3 months, 95% CI: -4.2 to 6.9). The type of IA diagnosis (definite/probable/possible) had no influence on 12-week (p=.13) or long-term survival (p=.61).
Prognostic impact of achieving complete response of invasive aspergillosis
Eighty-six patients were evaluated for IA response to treatment. The cumulative probability of CR and PR at 12 weeks was estimated at 20% in the non-voriconazole group and 38% in the voriconazole group (p=.074). In total, 30 patients achieved CR, 11 in the non-voriconazole group and 19 in the voriconazole group. The overall probability of CR was 25% and 45% in each group, respectively (p=.068). The median time to CR was 3 months (range 1 to 6) in the non-voriconazole group and 2 months (range 0.5 to 24) in the voriconazole group. While all CR cases were observed during the first 6 months in the non-voriconazole group, 6 out of the 19 CR cases in the voriconazole group occurred between 6 and 24 months. The probabilities displayed in Figures 2A and 2B illustrate that although a higher rate of CR was obtained in the voriconazole group, the overall mortality rate became similar in both groups after 12 to 18 months, with a lower probability of death without CR but a higher probability of death after CR. At 36 months, the probability of being alive after CR was 18.2% in the non-voriconazole group and 15.3% in voriconazole group (p=.72). Using multistate models, the time to achieve CR was not found to be significantly associated with survival (p=.47).
Causes of death
The cumulative incidence of deaths from the various causes is displayed in Figures 2C and   2D . Patients who did not receive voriconazole as a first-line treatment had a higher probability of dying from IA than those who received voriconazole (p=.004), with an 18-month cumulative incidence of deaths from IA of 47% (95% CI: 31-61%) as compared to 19% (95% CI: 9-33%) in the voriconazole group ( Figure 2C ). The 18-month cumulative incidence of deaths with IA was similar in both groups [29% (95% CI: 16-43%)] for the nonvoriconazole group and 38% (95% CI: 23-56%) for the voriconazole group, (p=.46). The 18-month cumulative incidence of deaths without IA was 4% (95% CI: 1-14%) in the nonvoriconazole group and 27% (95% CI: 14-42%) in the voriconazole group (p=.006) ( Figure   2D ). Finally, the 18-month cumulative incidence of deaths from and with IA was 76% (95% CI: 60-86%) in the non-voriconazole group and 57% (95% CI: 41-70%) in the voriconazole group (p=.021). Causes are listed in Table 1 . Noteworthy, the cumulative incidence at 12 months of deaths due to relapse of the underlying disease was 4% in the non-voriconazole group and 7% in the voriconazole group, and no significant difference in the cumulative incidence of relapse-related deaths over time was found (p=.13).
DISCUSSION
This single-centre retrospective study confirms previous findings indicating that first-line voriconazole treatment of allogeneic HSCT recipients with IA leads to a significant increase in 12-week survival through a decrease in IA-attributable mortality (2-4, 6). However, an unexpected finding was that first-line treatment with voriconazole, which has mostly been prescribed during the last decade, does not translate into an increase in long-term survival.
Our study once again demonstrates the clear positive impact of first-line voriconazole treatment on 12-week survival of HSCT patients. This impact has already been demonstrated in a large randomized trial of immunocompromised patients with IA, half of whom received first-line voriconazole. In this latter study, the 12-week survival rate was 71% in the voriconazole group and 58% in the control group (1). The difference was even larger (65% and 45%, respectively) in the subgroup of HSCT recipients (Herbrecht R, unpublished data).
These figures are completely in line with our study where the 12-week survival rate was 60% in the voriconazole group and 36% in the non-voriconazole group. Two other large retrospective and two prospective series of patients highlight the beneficial role of voriconazole on 12-week survival (2, 4, 6, 18 ). In addition, analyses of prognostic factors verify the other previously recognized important prognostic factors (uncontrolled GVHD, steroids dose) (2, 4, 7, 19, 20) . (23) . We previously reported a one-year survival rate of 22% for 26 patients with IA receiving transplants in our unit in 1994 (19) . The one-year survival rate of the present series, which includes none of these former 26 patients, is in line with previously published results. We could not identify any significant predictor of long-term mortality for patients living longer than 12 weeks. However, as only 25 patients died during this period, the power of these analyses was low. A noteworthy finding was that achieving a complete response to antifungal therapy is a prerequisite for long-term survival, although the time necessary to achieve this response did not seem to play any role. Although consistent with expectations, the mandatory achievement of complete IA response for long-term survival has not been previously reported. Conversely, complete IA response alone is not enough to ensure long-term survival because of subsequent fatal complications. Voriconazole significantly decreased IA-attributable mortality, as previously demonstrated (2, 4) . However, patients in the voriconazole group were unexpectedly found to experience a significantly higher mortality rate during follow-up, with GHVD and other infections as the main causes of death. Although these patients recovered from IA, they remained at high risk for other complications, which overwhelmed the initial survival benefit (24) .
There are several limitations to our study. Firstly, it is a retrospective study that includes patients treated more than a decade ago (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) . In this respect, the two groups of patients may not be directly comparable with some factors favouring the older group (e.g., more geno-identical donors in this group) and others favouring the more recent one (e.g., an earlier diagnosis illustrated by a smaller number of bilateral pulmonary IA). Furthermore, it cannot be excluded that the more recent group of patients was, independently of IA, more severely ill or immune-suppressed. It may well be the case that, in the non-voriconazole period, the most vulnerable patients died rapidly from IA while less severely ill patients were long-time survivors, and that voriconazole cured most patients with IA independently of the degree of underlying illness, leaving them at risk of other complications. Techniques for causal inference in observational data, such as propensity scores or marginal structural models, may have helped to diminish biases when comparing the two groups. The limited sample size, however, makes their use hazardous in the present study. Nevertheless, analyses adjusted for prognostic factors, which are a way to correct for group imbalances, also confirmed raw analyses. Invasive aspergillosis occurrence in allogeneic HSCT recipients should therefore be considered to be a strong marker of severe long-lasting immunosuppression and accompanying fatal complications. The second limitation is that during the study period, there was no homogeneous protocol for antifungal treatment response assessment. In most cases, clinical and imaging follow-up was the sole responsibility of the consulting physician, which renders the data concerning response times to antifungal treatment somewhat imprecise. However, response times did not seem to affect the outcome.
A third limitation is that very few autopsies were performed in this study, weakening the cause-of-death data. However, each patient chart was reviewed by two of the authors (GS1 and PR), and the same definitions were used for both groups of patients. A final limitation is that the number of patients in the present series is limited. However, this is a single-transplant department study and most results were obtained with such a high confidence level that it is unlikely that they could have been observed by chance alone.
This study clearly demonstrates that although the prognosis of IA after HSCT has dramatically improved with the preferential use of voriconazole as a first-line treatment, this major advance in patient care does not translate into increased long-term survival. With these patients, prolonged attention must be focused on GVHD treatment as well as infection prophylaxis, detection, and curative treatment. 
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